<?xml version="1.0" encoding="UTF-8"?>
<p id="para0032">Among the nucleoside analogues, remdesivir, an adenosine analogue, which was originally developed for treatment of Ebola virus disease, has been approved by FDA for clinical use in patients with COVID-19. Remdesivir incorporates into viral RNA during synthesis and inhibits replication of the virus. Because of its anti-viral effects against RNA viruses, including coronaviruses, FDA has approved its use in patients with COVID-19 on an emergency use basis. However, data on clinical efficacy of remdesivir, which has been tested in small to moderate sample size clinical studies, have been mixed and largely inconclusive 
 <xref rid="bib0056" ref-type="bibr">[56]</xref>, 
 <xref rid="bib0057" ref-type="bibr">[57]</xref>, 
 <xref rid="bib0058" ref-type="bibr">[58]</xref>, 
 <xref rid="bib0059" ref-type="bibr">[59]</xref>.
</p>
